Sun damage predisposes pediatric patients to melanoma
the ONA take:
According to new research published in the Journal of Investigational Dermatology, researchers from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project have found that melanoma in some adolescent and adult patients involve many of the same genetic mutations and would likely respond to the same treatment.
For the study, researchers included 23 patients ranging in age from 9 months of 19 years old with melanoma. Researchers sequenced each person's genome and found that among the 15 patients with conventional melanoma, their tumors included various genetic mutations that were mostly consistent with ultraviolet light damage.
"We were surprised to see that so many of the pediatric melanomas had genetic changes linked to UV damage," said Richard K. Wilson, Ph.D., director of The Genome Institute at Washington University School of Medicine in St. Louis.
"This in-depth look at the genomics of pediatric melanoma is extraordinarily important for diagnosis and for selecting treatments that give young patients the best chances of a cure."
Melanoma in some adolescent and adult patients involve many of the same genetic mutations and would likely respond to the same treatment.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|